Adlai Nortye

Adlai Nortye is a global biopharmaceutical company focused on transforming deadly cancers into chronic and eventually curable diseases. With research, development, and clinical operations centers in both China and the United States, Adlai Nortye is dedicated to creating innovative "global-new" oncology drugs. Their mission is to provide more effective treatment options for patients worldwide.

Adlai Nortye is committed to innovation through collaborative partnerships and independent research and development. The company's pipeline includes AN2025 (buparlisib), which has received FDA Fast Track designation, and AN0025 (palupiprant), an EP4 antagonist currently in Phase Ib clinical trials in combination with Keytruda® for multiple solid tumor patients and Phase II clinical trials in combination with chemoradiotherapy for locally advanced cancers. AN4005, an internally developed oral small molecule PD-L1 inhibitor, is currently in Phase I clinical trials in both China and the United States.

With its headquarters in 杭州, 浙江省, CN, and an additional location in New Jersey, US, Adlai Nortye is strategically positioned to develop and deliver innovative oncology therapies on a global scale. Adlai Nortye’s experienced management team and proprietary drug development platform, coupled with strategic partnerships with leading global pharmaceutical companies, enables it to bring more effective treatment options to patients in China and around the world.

To the manager of Adlai Nortye, we invite you to create a customized and exclusive company showcase and product listing on our platform.